Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy
- PMID: 22782418
- DOI: 10.1001/jama.2012.6131
Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy
Abstract
Context: Assessment of the fetal safety of vaccination against influenza A(H1N1)pdm09 in pregnancy has been limited.
Objective: To investigate whether exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes.
Design, setting, and participants: Registry-based cohort study based on all liveborn singleton infants in Denmark, delivered between November 2, 2009, and September 30, 2010. In propensity score-matched analyses, we estimated prevalence odds ratios (PORs) of adverse fetal outcomes, comparing infants exposed and unexposed to an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy.
Main outcome measures: Major birth defects, preterm birth, and small size for gestational age.
Results: From a cohort of 53,432 infants (6989 [13.1%] exposed to the influenza A[H1N1]pdm09 vaccine during pregnancy [345 in the first trimester and 6644 in the second or third trimester]), 660 (330 exposed) were included in propensity score-matched analyses of adverse fetal outcomes associated with first-trimester exposure. For analysis of small size for gestational age after second- or third-trimester exposure, 13,284 (6642 exposed) were included; for analyses of preterm birth, 12,909 (6543 exposed) were included. A major birth defect was diagnosed in 18 of 330 infants (5.5%) exposed to the vaccine in the first trimester, compared with 15 of 330 unexposed infants (4.5%) (POR, 1.21; 95% CI, 0.60-2.45). Preterm birth occurred in 31 of 330 infants (9.4%) exposed in the first trimester, compared with 24 of 330 unexposed infants (7.3%) (POR, 1.32; 95% CI, 0.76-2.31), and in 302 of 6543 infants (4.6%) with second- or third-trimester exposure, compared with 295 of 6366 unexposed infants (4.6%) (POR, 1.00; 95% CI, 0.84-1.17). Small size for gestational age was observed in 25 of 330 infants (7.6%) with first-trimester exposure compared with 31 of 330 unexposed infants (9.4%) (POR, 0.79; 95% CI, 0.46-1.37), and in 641 of 6642 infants (9.7%) with second- or third-trimester exposure, compared with 657 of 6642 unexposed infants (9.9%) (POR, 0.97; 95% CI, 0.87-1.09).
Conclusions: In this Danish cohort, exposure to an adjuvanted influenza A(H1N1)pdm09 vaccine during pregnancy was not associated with a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction.
Comment in
-
Influenza pandemics--pregnancy, pathogenesis, and perinatal outcomes.JAMA. 2012 Jul 11;308(2):184-5. doi: 10.1001/jama.2012.7911. JAMA. 2012. PMID: 22782421 No abstract available.
Similar articles
-
Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants.Vaccine. 2013 Oct 17;31(44):5026-32. doi: 10.1016/j.vaccine.2013.08.097. Epub 2013 Sep 7. Vaccine. 2013. PMID: 24016809
-
Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study.BMJ. 2014 May 29;348:g3361. doi: 10.1136/bmj.g3361. BMJ. 2014. PMID: 24874845 Free PMC article.
-
Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination.Vaccine. 2015 Sep 11;33(38):4850-7. doi: 10.1016/j.vaccine.2015.07.061. Epub 2015 Aug 1. Vaccine. 2015. PMID: 26238723
-
A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy.Int J Gynaecol Obstet. 2018 May;141(2):141-150. doi: 10.1002/ijgo.12394. Epub 2017 Dec 18. Int J Gynaecol Obstet. 2018. PMID: 29149524 Review.
-
The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis.Am J Perinatol. 2016 Sep;33(11):1104-14. doi: 10.1055/s-0036-1586101. Epub 2016 Sep 7. Am J Perinatol. 2016. PMID: 27603545 Review.
Cited by
-
Exploring the consent process among pregnant and breastfeeding women taking part in a maternal vaccine clinical trial in Kampala, Uganda: a qualitative study.BMC Med Ethics. 2024 May 16;25(1):57. doi: 10.1186/s12910-024-01055-7. BMC Med Ethics. 2024. PMID: 38755578 Free PMC article.
-
Prevalence of preterm birth in Scandinavian countries: a systematic review and meta-analysis.J Int Med Res. 2023 Oct;51(10):3000605231203843. doi: 10.1177/03000605231203843. J Int Med Res. 2023. PMID: 37843530 Free PMC article.
-
Safety of influenza vaccination during pregnancy: a systematic review.BMJ Open. 2023 Sep 6;13(9):e066182. doi: 10.1136/bmjopen-2022-066182. BMJ Open. 2023. PMID: 37673449 Free PMC article.
-
A study of acceptance and hesitation factors towards tetanus, diphtheria, and acellular pertussis (Tdap) and influenza vaccines during pregnancy.Vaccine X. 2023 Jul 7;14:100351. doi: 10.1016/j.jvacx.2023.100351. eCollection 2023 Aug. Vaccine X. 2023. PMID: 37519777 Free PMC article.
-
Immunization during pregnancy: do healthcare workers recommend vaccination against influenza?Front Public Health. 2023 Jun 2;11:1171142. doi: 10.3389/fpubh.2023.1171142. eCollection 2023. Front Public Health. 2023. PMID: 37333535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical